

# Antimicrobials for Multi-drug Resistant Gram Negative Bacilli (MDR GNB) & Availability in AHS

Antimicrobial Agent <sup>1</sup>	Activity	AHS acute care hospital Formulary Status/ Availability/Cost	Contact Information
Cefiderocol (Fetroja)	CRE CPE CRPA (incl. MBL) CRAB SM	<b>SAP<sup>4</sup></b> Shionogi has a compassionate use program for Canada; very laborious acquisition process. No charge; drug is donated by Shionogi at this time as part of participating in their phase IV postmarketing surveillance study.	Shionogi (800) 849-9707 medicalinformation@shionogi.com
Ceftazidime-avibactam (Avycaz)	CRE Class A + D CPE CRPA (non-MBL)	<b>SAP<sup>4</sup></b> <b>Sep 2020 - Not available due to a back order that is not expected to be resolved until sometime in 2022.</b>	Allergan Primary contact: Foo-Lim Yeh (Director, Regulatory Affairs): Yeh_Foo-Lim@Allergan.com Secondary contact: Rhiannon Konig (Senior Manager, Regulatory Affairs): Rhiannon.Konig@allergan.com 1-800-668-6424 ext 7353, Cell 416-435-2974 Email: <a href="mailto:MR-MedicalInformation@Allergan.com">MR-MedicalInformation@Allergan.com</a>
Ceftolozane-tazobactam (Zerbaxa)	CRE (non-CPP) CRPA (non-CPP) SM	<b>UR – STEDT</b> ASC/DTC recommended adding to formulary but awaiting AHS Exec approval of funding. <b>Recalled Dec 2020 and currently unavailable.</b> \$136.63/1.5g	Merck
Fosfomycin IV (Ivozfo)	CRE CPE CRPA (incl. MBL)	<b>NF – STEDT</b> \$19/gram	Verity Pharmaceuticals
Imipenem-relebactam (Recarbrio)	CRE Class A + D CPE CRPA (non-MBL)	<b>SAP<sup>4</sup></b> No charge	Merck
Meropenem-vaborbactam (Vabomere)	CRE Class A CPE	June 2020 - <b>No SAP process in place</b> , per Melinta	Melinta Therapeutics
Plazomicin (Zemdri)	CRE CPE CRPA (incl. MBL)	June 2020 - <b>No SAP requests to date</b> \$315USD/500 mg	Cipla USA Courtney.Barton@Cipla.com

## Antimicrobials for MDR GNB & Availability in AHS | 2

Antimicrobial Agent <sup>1</sup>	Activity	AHS acute care hospital Formulary Status/ Availability/Cost	Contact Information
Colistin	CRE <sup>2</sup> CPE <sup>2</sup> <b>CRPA</b> CRAB	<b>F</b> \$12.49/150mg	FRESENIUS KABI
Tigecycline (Tygacil)	CRE <sup>3</sup> CPE <sup>3</sup> CRAB SM	<b>FRG</b> Restricted to Infectious Diseases \$17.50/50mg	Pfizer

1. Susceptibility testing available for all of these agents, except fosfomycin IV for non-*E. coli* Enterobacterales. Contact microbiology lab.
2. Intrinsic resistance of: *Proteus* species, *Providencia* species, *Morganella morgannii*, *Serratia marcescens*
3. Intrinsic resistance of: *Proteus* species, *Providencia* species, *Morganella morgannii*
4. Special Access Programme contact information:  
Website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html>  
Phone: (613) 941-2108 (Must press 0 to reach an on-call officer)  
Fax: (613) 941-3194  
E-mail: [SAPdrugs@hc-sc.gc.ca](mailto:SAPdrugs@hc-sc.gc.ca)

CPE = carbapenemase-producing *Enterobacterales*  
Class A CPE – includes KPC, GES, NMC, SME, IMI carbapenemases  
Class D CPE – includes OXA carbapenemases

CPP: carbapenemase producer

CRAB = carbapenem-resistant *Acinetobacter baumannii*

CRE = carbapenem-resistant *Enterobacterales*

**CRPA = carbapenem-resistant *Pseudomonas aeruginosa***

F = formulary

FRG = formulary, restricted with guidelines

MBL: metallo-β-lactamase

NF = non-formulary

SAP = Special Access Programme request

SM = *Stenotrophomonas maltophilia*

STEDT = Short Term Exceptional Drug Therapy request

Acknowledgments: Tanis Dingle, MD; Susan Fryters, BScPharm, ACPR; Christine Ondro, PharmD

Reviewed by AHS Antimicrobial Stewardship Subcommittee, March 26, 2021

Approved by AHS Antimicrobial Stewardship Subcommittee, May 28, 2021

Last updated: May 28, 2021